![]() ![]() ![]() Shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybinĬompass management team to host an investor conference call today at 1.00pm UK (8.00am ET)Ĭompass Pathways plc (Nasdaq: CMPS) (“Compass”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that its groundbreaking phase 2b clinical trial of COMP360 psilocybin therapy for treatment-resistant depression has achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a highly statistically significant and clinically relevant reduction in depressive symptom severity after three weeks, with a rapid and durable treatment response*. Largest randomised, controlled, double-blind psilocybin therapy study ever completed ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |